AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

NOV Inc. (NYSE:NOV) +1.3% in Monday's trading despite receiving a downgrade to Neutral from Buy with an $18 price target at ...

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...

Plains All American Pipeline misses revenue but beats earnings in Q3 2024. Learn why PAA stock offers strong yield and ...

Trump's potential economic policies include tariffs, deregulation, and immigration reforms, which could impact inflation, job ...

Lumine Group is focused on acquiring and optimizing TMT software companies. Learn why LMGIF stock is a Hold for now, despite ...

Grupo Financiero Galicia is benefiting from a rebound in private sector lending activity in Argentina. Market forecasts see ...

Nextracker boasts strong fundamentals, including high profit margins, double-digit revenue growth, and a solid balance sheet, ...

Gold prices retreat as the US Dollar strengthens as hopes of aggressive rate cuts fade. China’s economic slowdown concerns ...

Boeing's preferred stock offers a 5.6% yield with dividends paid quarterly starting January 2025. Read why mandatory ...

VanEck Fallen Angel High Yield Bond ETF offers a 6.32% SEC yield but has lagged inflation. Learn why ANGL ETF may be less ...

Savers Value Village, a major for-profit thrift retailer, shows modest revenue growth but mixed profitability, yet remains ...